A. K. Sinha

Biochemistry, Genetics and Molecular BiologyMedicineMathematicsAgricultural and Biological Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy”.

US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy

Journal of Clinical Oncology(2024)10.1200/jco.24.00546

N/A

0.584DataRank · unranked

15 citations

Diana Bradford, A. K. Sinha, Pallavi S. Mishra‐Kalyani, Catherine C. Lerro, Donna R. Rivera +13 more

Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4912

N/A

0DataRank · unranked

29 citations

Mallorie H. Fiero, Erik Bloomquist, A. K. Sinha, Steven J. Lemery, Harpreet Singh +13 more

FDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3699

N/A

0DataRank · unranked

47 citations

Erin Larkins, A. K. Sinha, Pallavi S. Mishra‐Kalyani, Samina Jafri, Shyam Kalavar +6 more

FDA Approval Summary: Vorasidenib for IDH -Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1333

N/A

0DataRank · unranked

12 citations

Amy Barone, Stephanie Aungst, Claudia P. Miller, Suryatheja Ananthula, Youwei Bi +20 more